Our portfolio

Expanded LMIC access to single-pill HIV treatment

Aurobindo Pharma, along with Mylan Laboratories, received support from the foundation to expand the low-price distribution to low- and middle-income populations of a single-pill HIV treatment containing dolutegravir.
Website
  • Domain
    Healthcare Delivery
  • Investment type
    Volume guarantee
  • Status
    Exit
  • Initial investment
    Public
  • Partnered in
    2017
  • Investment lead
    Natalie Revelle
  • Headquarters
    India
  • Program strategy
    HIV

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.